ArticleChemical communications (Cambridge, England)2017
Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
Article in Chemical communications (Cambridge, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 73 citations in OpenAlex.
- Structure over States: Planarity, Not Energy, Dictates Photoactivation in Ru(II) PACT Agents.Journal of the American Chemical Society · 2025Article
- Mixed Ru(II)-Ir(III) Complexes as Photoactive Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4.Inorganic chemistry · 2024Article
- Ru(II) Oligothienyl Complexes with Fluorinated Ligands: Photophysical, Electrochemical, and Photobiological Properties.Inorganic chemistry · 2024Article
- The Impact of Inorganic Systems and Photoactive Metal Compounds on Cytochrome P450 Enzymes and Metabolism: From Induction to Inhibition.Biomolecules · 2024Review
- Control of metalloenzyme activity using photopharmacophores.Coordination chemistry reviews · 2024Article
- Ru(II) Phenanthroline-Based Oligothienyl Complexes as Phototherapy Agents.Inorganic chemistry · 2023Article
- Low-Temperature Observation of the Excited-State Decay of Ruthenium-(Mono-2,2':6',2″-Terpyridine) Ions with Innocent Ligands: DFT Modeling of anACS omega · 2023Article
- Ru(II) photocages enable precise control over enzyme activity with red light.Nature communications · 2022Article
- Intraligand Excited States Turn a Ruthenium Oligothiophene Complex into a Light-Triggered Ubertoxin with Anticancer Effects in Extreme Hypoxia.Journal of the American Chemical Society · 2022Article
- Photocytotoxicity and photoinduced phosphine ligand exchange in a Ru(ii) polypyridyl complex.Chemical science · 2022Article
- Fine-Feature Modifications to Strained Ruthenium Complexes Radically Alter Their Hypoxic Anticancer ActivityPhotochemistry and photobiology · 2022Article
- Taking phototherapeutics from concept to clinical launch.Nature reviews. Chemistry · 2021Review
- Trifluoromethyl substitution enhances photoinduced activity against breast cancer cells but reduces ligand exchange in Ru(ii) complex.Chemical science · 2021Article
- The Development of Ru(II)-Based Photoactivated Chemotherapy Agents.Molecules (Basel, Switzerland) · 2021Review
- Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4.Journal of the American Chemical Society · 2021Article
- Modification of amyloid-beta peptide aggregationChemical science · 2021Article
- Photorelease of a metal-binding pharmacophore from a Ru(II) polypyridine complex.Dalton transactions (Cambridge, England : 2003) · 2021Article
- Visible-to-NIR-Light Activated Release: From Small Molecules to Nanomaterials.Chemical reviews · 2020Article
- Ru(II)-diimine complexes and cytochrome P450 working hand-in-hand.Journal of inorganic biochemistry · 2020Review
- Breaking the barrier: an osmium photosensitizer with unprecedented hypoxic phototoxicity for real world photodynamic therapy.Chemical science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
New Ru(ii)-caged abiraterone complexes were synthesized that exhibit strong absorption in the visible region and release the steroidal CYP17A1 inhibitor abiraterone upon exposure to low energy visible light in buffer and prostate cancer cells. Photoinduced release results in abiraterone binding to its CYP17A1 target in an inhibitory mode.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.